Cargando…

Protocol for a randomised controlled trial of the combined effects of the GLP-1 receptor agonist liraglutide and exercise on maintenance of weight loss and health after a very low-calorie diet

INTRODUCTION: The success rate of weight loss maintenance is limited. Therefore, the purpose of this study is to investigate the maintenance of weight loss and immunometabolic health outcomes after diet-induced weight loss followed by 1-year treatment with a glucagon-like peptide-1 receptor agonist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Simon Birk Kjær, Lundgren, Julie Rehné, Janus, Charlotte, Juhl, Christian Rimer, Olsen, Lisa Møller, Rosenkilde, Mads, Holst, Jens Juul, Stallknecht, Bente Merete, Madsbad, Sten, Torekov, Signe Sørensen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830609/ https://www.ncbi.nlm.nih.gov/pubmed/31678947 http://dx.doi.org/10.1136/bmjopen-2019-031431

Ejemplares similares

Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment
por: Jensen, Simon Birk Kjær, et al.
Publicado: (2022)

Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
por: Sandsdal, Rasmus M., et al.
Publicado: (2023)

Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial
por: Andersen, Emil, et al.
Publicado: (2022)

Insufficient sleep predicts poor weight loss maintenance after 1 year
por: Bogh, Adrian F, et al.
Publicado: (2022)

Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans
por: Asmar, Meena, et al.
Publicado: (2010)

Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
por: Iepsen, E W, et al.
Publicado: (2015)

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB
por: Engelbrechtsen, L., et al.
Publicado: (2017)

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
por: Iepsen, Eva W., et al.
Publicado: (2020)

N‐terminal alterations turn the gut hormone GLP‐2 into an antagonist with gradual loss of GLP‐2 receptor selectivity towards more GLP‐1 receptor interaction
por: Gabe, Maria Buur Nordskov, et al.
Publicado: (2022)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy
por: Sampson Kjeldsen, Sasha Alexandra, et al.
Publicado: (2023)

Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
por: Hansen, Christian Stevns, et al.
Publicado: (2019)

Proteomics reveals the effects of sustained weight loss on the human plasma proteome
por: Geyer, Philipp E, et al.
Publicado: (2016)

The Antiresorptive Effect of GIP, But Not GLP‐2, Is Preserved in Patients With Hypoparathyroidism—A Randomized Crossover Study
por: Skov‐Jeppesen, Kirsa, et al.
Publicado: (2021)

A Pilot Study Showing Acute Inhibitory Effect of GLP‐1 on the Bone Resorption Marker CTX in Humans
por: Nissen, Anne, et al.
Publicado: (2019)

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy
por: Kjeldsen, Sasha A.S., et al.
Publicado: (2023)

Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men
por: Janus, Charlotte, et al.
Publicado: (2019)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)

From the Incretin Concept and the Discovery of GLP-1 to Today's Diabetes Therapy
por: Holst, Jens Juul
Publicado: (2019)

Gain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case report
por: Zhang, Jinyi, et al.
Publicado: (2020)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Liraglutide improves the beta-cell function without increasing insulin secretion during a mixed meal in patients, who exhibit well-controlled type 2 diabetes and coronary artery disease
por: Anholm, Christian, et al.
Publicado: (2019)

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes—a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study
por: Dejgaard, Thomas Fremming, et al.
Publicado: (2015)

What combines best with GLP-1 for obesity treatment: GIP receptor agonists or antagonists?
por: Holst, Jens Juul
Publicado: (2021)

The anorexic hormone Peptide YY(3–36) is rapidly metabolized to inactive Peptide YY(3–34) in vivo
por: Toräng, Signe, et al.
Publicado: (2015)

Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion: A case report
por: Dirksen, Carsten, et al.
Publicado: (2010)

Skeletal muscle structural lipids improve during weight-maintenance after a very low calorie dietary intervention
por: Haugaard, Steen B, et al.
Publicado: (2009)

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide
por: Flint, Anne, et al.
Publicado: (2010)

The Sensory Mechanisms of Nutrient-Induced GLP-1 Secretion
por: Hjørne, Anna Pii, et al.
Publicado: (2022)

Effects of 6 Months of Active Commuting and Leisure-Time Exercise on Fibrin Turnover in Sedentary Individuals with Overweight and Obesity: A Randomised Controlled Trial
por: Gram, Anne Sofie, et al.
Publicado: (2018)

The Imaging of Insulinomas Using a Radionuclide-Labelled Molecule of the GLP-1 Analogue Liraglutide: A New Application of Liraglutide
por: Lv, Jing, et al.
Publicado: (2014)

Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss()
por: Holst, Jens Juul, et al.
Publicado: (2018)

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
por: Shi, Shaomin, et al.
Publicado: (2023)

Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake
por: Bojsen-Møller, Kirstine Nyvold, et al.
Publicado: (2023)

GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
por: Holst, Jens Juul, et al.
Publicado: (2020)

Effects of Exercise Domain and Intensity on Sleep in Women and Men with Overweight and Obesity
por: Quist, Jonas Salling, et al.
Publicado: (2019)

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
por: Jonsson, Isabella, et al.
Publicado: (2021)

What is Diabetes Remission?
por: Holst, Jens J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c662ogseals9h6qemis9nds6rn